Pfizer Inc. (NYSE:PFE) Shares Acquired by Martingale Asset Management L P

Martingale Asset Management L P boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 416.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 127,129 shares of the biopharmaceutical company's stock after acquiring an additional 102,521 shares during the quarter. Martingale Asset Management L P's holdings in Pfizer were worth $3,373,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of PFE. Nordea Investment Management AB increased its stake in Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after buying an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI increased its position in shares of Pfizer by 118.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after acquiring an additional 159,984 shares during the period. Copley Financial Group Inc. acquired a new stake in shares of Pfizer in the third quarter valued at $577,000. Mcdonald Partners LLC boosted its holdings in Pfizer by 9.9% in the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock valued at $2,926,000 after purchasing an additional 9,963 shares during the period. Finally, Merit Financial Group LLC grew its stake in Pfizer by 60.8% during the 4th quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock worth $3,395,000 after purchasing an additional 48,397 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Pfizer Stock Performance

Shares of PFE stock traded up $0.13 during trading hours on Monday, hitting $22.04. The stock had a trading volume of 21,777,811 shares, compared to its average volume of 47,873,695. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $125.00 billion, a PE ratio of 15.63, a PEG ratio of 0.64 and a beta of 0.67. The stock's 50 day moving average is $25.25 and its 200 day moving average is $26.38. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

PFE has been the topic of a number of analyst reports. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group decreased their price target on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a research note on Tuesday, April 8th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and a consensus target price of $31.07.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.